Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most
common type being venous thromboembolism (VTE). Several risk factors for developing …

Patients with cancer are at a high risk of symptomatic venous thromboembolism (VTE),
which is a common cause of morbidity and mortality in this patient population. Increased risk …

Efficacy and safety of anticoagulant treatment for venous thromboembolism (VTE) may vary
in patients with different cancer sites. We evaluated the rates of VTE recurrence and major …

Cancer-associated arterial thrombotic events (ATEs) are increasingly recognized in specific
malignancies and in association with the expanding armamentarium of novel …

Cancer patients are at higher risk for venous thromboembolism (VTE). Several risk
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …

Introduction Venous thromboembolism (VTE) is a frequent clinical event in patients with
gynecologic cancer. However, studies that exclusively address the incidence of VTE …

Background The risk of thromboembolic events is increased in patients with non-valvular
atrial fibrillation (NVAF) and renal impairment. The risk of bleeding events is increased if …

Cancer-associated thrombosis (CAT) is a leading cause of mortality in cancer patients and
its incidence varies in different parts of the world. Venous thromboembolism (VTE) is a …

Objective To explore the efficacy and safety of direct oral factor Xa inhibitors in the treatment
of cancer-associated acute venous thromboembolism (VTE). Patients and Methods …

Malignancy is a significant risk factor for venous thromboembolism (VTE). It is estimated that
up to 20% of patients with cancer may develop VTE at some time in their cancer journey …